
Ovid Technologies is a leading provider of clinical trial management and regulatory compliance solutions for the life sciences industry. Ovid Technologies was founded in 1995 and is headquartered in New York City.
The company's flagship product, Ovid, is a comprehensive clinical trial management system that streamlines the clinical trial process from start to finish. This includes electronic data capture, clinical trial management, and regulatory compliance.
Ovid Technologies has a strong track record of innovation, with a focus on delivering cutting-edge technology and exceptional customer support.
Performance
The performance of Ovid Therapeutics stock has been quite volatile in recent years. The 52-week high is a staggering US$4.10, while the 52-week low is a lowly US$0.68.
The stock's beta is a relatively low 0.34, indicating that its price movements tend to be less volatile compared to the overall market. However, this hasn't stopped the stock from experiencing significant price swings, with a 1-month change of -24.97% and a 3-month change of -36.70%.
In the past year, the stock has plummeted by an astonishing -81.48%, while its 3-year change is a -74.46% decline. The 5-year change is an even more dramatic -80.06%. If you had invested in Ovid Therapeutics at its IPO, you would have seen a -94.06% decline in the stock's value.
Here's a summary of the stock's performance over different time periods:
The stock's previous close was US$0.732, with a day range of US$0.7 to US$0.758. The year range is even more dramatic, with a low of US$0 and a high of US$4. The stock's market capitalization is a relatively modest US$51,965,000, and it's listed on the NASDAQ exchange.
In terms of financial performance, Ovid Therapeutics has reported a diluted EPS (TTM) of -0.46. The company's revenue growth year-over-year (YOY) is a respectable 58.7%, while its earnings growth YOY is a flat 0%. The profit margin is also a zero, indicating that the company is not generating any profits.
Analysts are predicting a significant increase in the stock's price, with an average target of US$4.04. This represents a potential increase of 455.02% from the current stock price of US$0.73. However, it's worth noting that the analysts' predictions are quite varied, with a low estimate of US$1.20 and a high estimate of US$8.00.
A different take: S B I Card Share Price
Company Information
Ovid Technologies is a global provider of clinical trial management and regulatory information management solutions.
Ovid Technologies is a subsidiary of Wolters Kluwer, a multinational information services and publishing company.
Wolters Kluwer is headquartered in Alphen aan den Rijn, Netherlands, and has operations in over 180 countries.
Ovid Technologies has a presence in major markets globally, including North America, Europe, and Asia Pacific.
Featured Images: pexels.com


